Toward a Choice of Agents to Prevent Venous Thromboembolism After Gynecologic Cancer Surgery

Oral apixaban appeared to be a safe alternative to subcutaneous enoxaparin in women undergoing surgery for gynecologic malignancies.

Following surgery for gynecologic malignancies, almost 1 month of subcutaneous low-molecular-weight heparin is recommended to prevent venous thromboembolism (VTE); however, patients' adherence to this regimen is suboptimal. As oral apixaban, a factor Xa antagonist, is an effective anticoagulant after various surgical procedures, researchers conducted a randomized trial of 28 days of subcutaneous enoxaparin (40 mg daily) versus oral apixaban (2.5 mg twice daily) in 400 women (median age, 58) undergoing open or minimally invasive surgery for gynecologic cancer. All participants received subcutaneous heparin before and after surgery until they were deemed safe for randomization; the two groups did not differ regarding race/ethnicity, cancer st…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Toward a Choice of Agents to Prevent Venous Thromboembolism After Gynecologic Cancer Surgery

Topics

Reviewing Author